id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-321976-ao3bg8xi	Robinson, Philip C	Management of autoimmune disease during the COVID-19 pandemic	2020-08-18		.txt	text/plain	1019	66	47	So far there has not been any increase in the risk of hospitalisation for COVID-19 in rheumatic disease patients taking disease-modifying antirheumatic drugs alone (e.g. methotrexate) or in combination with biologics or Janus kinase inhibitors, compared to patients who were not taking these drugs. 1 Another study of people infected with COVID-19 compared 52 patients with rheumatic disease, including 39 taking immunosuppressants, with 104 matched COVID-19 positive controls. 3 In a series of 525 patients with inflammatory bowel disease, poorer outcomes with COVID-19 were associated with increasing age, comorbidities and systemic glucocorticoids. 4 When advising patients taking immunosuppressive drugs during the pandemic, a comprehensive risk assessment should consider the consequences of changing treatment. When coronavirus disease (COVID-19) emerged, there was concern regarding the potential for poor outcomes in patients taking immunosuppressive drugs for rheumatic diseases. American College of Rheumatology guidance for the management of rheumatic disease in adult patients during the COVID-19 pandemic: Version 1	./cache/cord-321976-ao3bg8xi.txt	./txt/cord-321976-ao3bg8xi.txt